The NeurologyLive® Parkinson disease Disease Spotlight page gives readers key updates and detailed coverage on the most recent expert conversations and data presentations relevant to the treatment of the movement disorder.
May 11th 2024
In a recent study assessing basal ganglia activity during REM sleep, results revealed that elevated beta power may be correlated with the severity of REM sleep behavior disorder in Parkinson disease.
Research Identifies Protective Drugs Toward Parkinson Disease, Warranting Future Consideration
January 16th 2023Plain sulfonamide diuretics was identified as a drug chemical subgroup potentially inversely associated with Parkinson disease risk, while weaker signals included insulin and ß2-adrenergic agonists.
Pimavanserin Lowers Mortality Better in Parkinson Disease Than Other Atypical Antipsychotics
January 6th 2023Findings from a large-scale trial of adults aged 65 and older with Parkinson disease showed that treatment with pimavanserin was associated with lower risk of mortality than other atypical antipsychotics.
Range of Risk Factors, Comorbidities, and Prodromal Features Identified Prior to Parkinson Disease
December 9th 2022Subsequent diagnosis of Parkinson disease was associated with a range of risk factors such as alcohol misuse and traumatic head injury, along with several other comorbidities and prodromal features.